GSK
8 months ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC)

For media and investors only- EAGLE-1 trial met its primary efficacy endpoint of non-inferiority comparing gepotidacin with intramuscular ceftriaxone plus oral azithromycin combination... Read More
GSK
9 months ago ⋅ English ⋅ 4 min read
Newsroom
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges

For media and investors only- Data Safety Monitoring Board (DSMB) for ACTG study recommends study be modified to stop randomisation and to give participants receiving daily oral therapy... Read More
GSK
9 months ago ⋅ English ⋅ 2 min read
Newsroom
GSK completes acquisition of Aiolos Bio

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on a... Read More
GSK
9 months ago ⋅ English ⋅ 3 min read
Newsroom
GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B

For media and investors only- Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)GSK plc (LSE/NYSE: GSK) ann... Read More
GSK
9 months ago ⋅ English ⋅ 4 min read
Newsroom
GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk

For media and investors only- Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population- Adults aged... Read More
GSK
9 months ago ⋅ English ⋅ 4 min read
Newsroom
GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration

For media and investors only- Shingrix already approved in China for adults aged 50 years and over- Application could expand populations eligible to benefit from protection against shin... Read More